Dashboard
1
High Debt company with Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of 1.21% and Operating profit at -6.41% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
EUR 32,985 Million ()
9.00
NA
0.00%
1.22
10.34%
1.12
Revenue and Profits:
Net Sales:
10,739 Million
(Quarterly Results - Jun 2025)
Net Profit:
-190 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
19.94%
0%
19.94%
6 Months
34.72%
0%
34.72%
1 Year
74.82%
0%
74.82%
2 Years
8.08%
0%
8.08%
3 Years
-38.69%
0%
-38.69%
4 Years
-24.02%
0%
-24.02%
5 Years
-29.57%
0%
-29.57%
Bayer AG for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
1.70%
EBIT Growth (5y)
60.44%
EBIT to Interest (avg)
2.34
Debt to EBITDA (avg)
3.73
Net Debt to Equity (avg)
1.09
Sales to Capital Employed (avg)
0.59
Tax Ratio
5.01%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.07%
ROCE (avg)
8.66%
ROE (avg)
15.91%
Valuation key factors
Factor
Value
P/E Ratio
9
Industry P/E
Price to Book Value
0.87
EV to EBIT
12.05
EV to EBITDA
7.31
EV to Capital Employed
0.94
EV to Sales
1.30
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
7.78%
ROE (Latest)
9.45%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot : Jun 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 2 Foreign Institutions (0.07%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
10,739.00
11,144.00
-3.63%
Operating Profit (PBDIT) excl Other Income
1,857.00
2,072.00
-10.38%
Interest
495.00
682.00
-27.42%
Exceptional Items
-1,002.00
-514.00
-94.94%
Consolidate Net Profit
-190.00
-26.00
-630.77%
Operating Profit Margin (Excl OI)
147.60%
83.50%
6.41%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -3.63% vs 0.91% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -630.77% vs 98.62% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
46,606.00
47,637.00
-2.16%
Operating Profit (PBDIT) excl Other Income
8,529.00
12,342.00
-30.89%
Interest
1,959.00
1,735.00
12.91%
Exceptional Items
-6,368.00
-7,606.00
16.28%
Consolidate Net Profit
-2,546.00
-2,942.00
13.46%
Operating Profit Margin (Excl OI)
96.10%
176.50%
-8.04%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -2.16% vs -6.11% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 13.46% vs -170.62% in Dec 2023
About Bayer AG 
Bayer AG
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






